The program supports investigator-sponsored clinical studies (ISS) or investigator-initiated trials (IIT). Our goal: to offer researchers and clinicians the opportunity to explore new indications, expand the use of Pentalafen®/Heliance® combination therapy, and push the boundaries of photodynamic therapy in cancer treatment. The ISS program is open to European and American surgeons and oncologists and allows …
To mark its fifth anniversary, Hemerion organized an exceptional Scientific Board Meeting at the Maison de la Chimie in Paris, open to investors and major players in the MedTech and Pharma/Biotech industries. The aim of this event was to unveil the latest clinical advances in glioblastoma and explore the potential of the Pentalafen/Heliance combination therapy …
Following the launch of its latest clinical study in the US, Hemerion has obtained authorization from the ANSM (French National Agency for Medicines and Health Products Safety) to open a new trial center at Lille University Hospital in July 2025.This opening confirms Hemerion’s ability to work effectively with health authorities on both sides of the …
Dr. Everardo Saad joins Hemerion as Medical Director. The appointment of this expert in oncology clinical trials marks Hemerion’s entry into a new phase of clinical investigation, with the upcoming launch of a pivotal study dedicated to its Pentalafen® / Heliance® technology in the treatment of glioblastoma and the expansion of its pipeline to other …
Hemerion participated for the first time this year in the Annual Meeting of the Congress of Neurosurgeons, the world’s largest event dedicated to neurosurgery, held in Los Angeles. Its combined Pentalafen®/Heliance® therapy attracted the attention of practitioners from around the world, as well as leading names in medtech. The Hemerion team presented its Heliance®/Pentalafen® combination …
In response to the acceleration of its preclinical and clinical research programs, Hemerion appointed Mélanie Rose to lead the innovation and expansion of its therapeutic solution pipeline based on Pentalafen® Heliance® technology. Already in an advanced clinical stage for the treatment of glioblastoma, this therapeutic platform could quickly find new applications in oncology as a complement …
Hemerion continues its international expansion with its first participation in the world’s largest neurosurgery event. This is an opportunity to preview its upcoming pivotal multicenter clinical trial to the most influential specialists in global neurosurgery. The Annual Meeting of the Congress of Neurosurgeons will be held at the Los Angeles Convention Center from October 10 …
Highly advanced in the clinical development of its glioblastoma treatment, Hemerion initiated a new research project in May with the GIGA Institute at the University of Liège. The objective is to validate the effectiveness of Hemerion’s technology on radioresistant tumor cells: a major challenge for improving the treatment of many other cancers. Hemerion began a …
As part of the delegation led by Business France, Hemerion is participating in the new edition of BIO held in Boston: an opportunity to forge new scientific partnerships and accelerate the development of its therapeutic innovations, particularly in the treatment of brain cancer. Hemerion will participate in Bio Convention 2025, held in Boston from June …
In the first quarter of 2025, Hemerion completed a Series A funding round totaling over €6.5 million. This new fundraising follows initial rounds in 2022 and 2023, which raised a total of €5.5 million, bringing the total amount raised by Hemerion since its creation in late 2020 to over €14 million. Hemerion’s successful funding round …